Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Junqueira Kipnis, Ana Paula ^a   De Oliveira, Fábio Muniz ^a   Trentini, Monalisa Martins ^a   Tiwari, Sangeeta ^b   Chen, Bing ^b   Resende, Danilo Pires ^a   Silva, Bruna D S ^a   Chen, Mei ^b   Tesfa, Lydia ^b   Jacobs Jr , William R ^b   Kipnis, André ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM SMEGMATIS RECOMBINANT VACCINE; MYCOBACTERIUM VACCINE; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM TRANSFORMATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; EX VIVO STUDY; FEMALE; GENE SEQUENCE; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LUNG; MOUSE; MURINE MODEL; MYCOBACTERIUM SMEGMATIS; NONHUMAN; RECOMBINANT GENE; RECOMBINANT PLASMID; SPLEEN; TUBERCULOSIS; VACCINATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY;

ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; MICE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84892575544     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078639     Document Type: Article

References (54)

1. WHO (2012) Global tuberculosis report 2012.
2. Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
3. Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, et al. (2012) Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379: 1902-1913.
4. Rabahi MF, Junqueira-Kipnis AP, Dos Reis MC, Oelemann W, Conde MB (2007) Humoral response to HspX and GlcB to previous and recent infection by Mycobacterium tuberculosis. BMC Infect Dis 7: 148.
5. Reis MC, Rabahi MF, Kipnis A, Junqueira-Kipnis AP (2009) Health care workers humoral immune response against GLcB, MPT51 and HSPX from Mycobacterium tuberculosis. Braz J Infect Dis 13: 417-421.
6. Reis MC, Silva BD, Sousa EM, Junqueira-Kipnis AP (2011) Role of antibodies reactive to HspX in discriminating pulmonary tuberculosis contacts with high risk of developing active disease. Braz J Infect Dis 15: 617-618.
7. Bretl DJ, He H, Demetriadou C, White MJ, Penoske RM, et al. (2012) MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun 80: 3018-3033.
8. de Araujo-Filho JA, Vasconcelos ACJr., de Sousa EM, Kipnis A, Ribeiro E, et al. (2008) Cellular responses to MPT51, GlcB and ESAT-6 among MDR-TB and active tuberculosis patients in Brazil. Tuberculosis (Edinb) 88: 474-481.
9. Melo CCA, Vasconcelos ACJr., Kipnis A, Andrade AL, Junqueira-Kipnis AP (2008) Humoral immune responses of tuberculosis patients in Brazil indicate recognition of Mycobacterium tuberculosis MPT-51 and GlcB. Clin Vaccine Immunol 15: 579-581.
10. Achkar JM, Jenny-Avital E, Yu X, Burger S, Leibert E, et al. (2010) Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected tuberculosis in the United States compared by HIV status. Clin Vaccine Immunol 17: 384-392.
11. Costa ACR, Guerreiro MCG; Silva, BDS, Trentini, MM, Junqueira-Kipnis, AP (2011.) Resposta Imune Humoral ao antígeno rGroEs do Mycobacterium tuberculosis em pacientes com tuberculose e seus contatos domiciliares. Revista de Patologia Tropical (Impresso) 40: p.23-34.
12. Kashyap RS, Shekhawat SD, Nayak AR, Purohit HJ, Taori GM, et al. (2013) Diagnosis of tuberculosis infection based on synthetic peptides from Mycobacterium tuberculosis antigen 85 complex. Clin Neurol Neurosurg 115: 678-683.
13. Limongi LC, Olival L, Conde MB, Junqueira-Kipnis AP (2011) Determination of levels of specific IgA to the HspX recombinant antigen of Mycobacterium tuberculosis for the diagnosis of pleural tuberculosis. J Bras Pneumol 37: 302-307.
14. Silva BD, da Silva EB, do Nascimento IP, Dos Reis MC, Kipnis A, et al. (2009) MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis. Vaccine 27: 4402-4407.
15. de Sousa EM, da Costa AC, Trentini MM, de Araujo Filho JA, Kipnis A, et al. (2012) Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. PLoS One 7: e47781.
16. Lim EM, Rauzier J, Timm J, Torrea G, Murray A, et al. (1995) Identification of mycobacterium tuberculosis DNA sequences encoding exported proteins by using phoA gene fusions. J Bacteriol 177: 59-65.
17. Pavelka MS, Jr., Jacobs WR, Jr. (1999) Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J Bacteriol 181: 4780-4789.
18. Bardarov S, Bardarov Jr S, Jr., Pavelka Jr MS, Jr., Sambandamurthy V, Larsen M, et al. (2002) Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148: 3007-3017.
19. Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, et al. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17: 1261-1268.
20. Lindenstrom T, Woodworth J, Dietrich J, Aagaard C, Andersen P, et al. (2012) Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun 80: 3533-3544.
21. Zhang H, Peng P, Miao S, Zhao Y, Mao F, et al. (2010) Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice. Scand J Immunol 72: 349-357.
22. Kuehnel MP, Goethe R, Habermann A, Mueller E, Rohde M, et al. (2001) Characterization of the intracellular survival of Mycobacterium avium ssp. paratuberculosis: phagosomal pH and fusogenicity in J774 macrophages compared with other mycobacteria. Cell Microbiol 3: 551-566.
23. Cheadle EJ, O'Donnell D, Selby PJ, Jackson AM (2005) Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 73: 784-794.
24. Bohsali A, Abdalla H, Velmurugan K, Briken V (2010) The non-pathogenic mycobacteria M. smegmatis and M. fortuitum induce rapid host cell apoptosis via a caspase-3 and TNF dependent pathway. BMC Microbiol 10: 237.
25. Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, et al. (2006) Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 80: 1645-1652.
26. Young SL, Murphy M, Zhu XW, Harnden P, O'Donnell MA, et al. (2004) Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int J Cancer 112: 653-660.
27. Yang C, He YL, Zhang L, Xu L, Yi Z, et al. (2009) GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine. Int J Tuberc Lung Dis 13: 1360-1366.
28. Yi Z, Fu Y, Yang C, Li J, Luo X, et al. (2007) Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice. Vaccine 25: 638-648.
29. da Silva EB, Silva BD, Leon JR, Kipnis A, Santos IK, et al. (2011) Using BCG, MPT-51 and Ag85 as antigens in an indirect ELISA for the diagnosis of bovine tuberculosis. Vet J 187: 276-278.
30. Taylor JL, Wieczorek A, Keyser AR, Grover A, Flinkstrom R, et al. (2012) HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol Cell Biol 90: 945-954.
31. Geluk A, van den Eeden SJ, van Meijgaarden KE, Dijkman K, Franken KL, et al. (2012) A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice. Vaccine 30: 7513-7521.
32. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
33. Maassen CB, Boersma WJ, van Holten-Neelen C, Claassen E, Laman JD (2003) Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine 21: 2751-2757.
34. Torrado E, Cooper AM (2010) IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 21: 455-462.
35. Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, et al. (2011) Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog 7: e1002378.
36. Bogdan C, Moll H, Solbach W, Rollinghoff M (1990) Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 20: 1131-1135.
37. Flynn JL (2006) Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8: 1179-1188.
38. Ulrichs T, Kaufmann SH (2006) New insights into the function of granulomas in human tuberculosis. J Pathol 208: 261-269.
39. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890-893.
40. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40: 279-290.
41. Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, et al. (2008) Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol 9: 13.
42. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, et al. (2002) Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3: 852-858.
43. Zaph C, Uzonna J, Beverley SM, Scott P (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 10: 1104-1110.
44. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
45. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, et al. (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81: 12071-12076.
46. Ciuffreda D, Comte D, Cavassini M, Giostra E, Buhler L, et al. (2008) Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 38: 2665-2677.
47. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
48. Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, et al. (2009) Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 4: e5930.
49. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, et al. (2009) HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 180: 1262-1270.
50. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, et al. (2010) Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 40: 2211-2220.
51. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, et al. (2011) Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187: 2222-2232.
52. Kremer L, Maughan WN, Wilson RA, Dover LG, Besra GS (2002) The M. tuberculosis antigen 85 complex and mycolyltransferase activity. Lett Appl Microbiol 34: 233-237.
53. Wilson RA, Maughan WN, Kremer L, Besra GS, Futterer K (2004) The structure of Mycobacterium tuberculosis MPT51 (FbpC1) defines a new family of non-catalytic alpha/beta hydrolases. J Mol Biol 335: 519-530.
54. Siddiqui KF, Amir M, Agrewala JN (2011) Understanding the biology of 16 kDa antigen of Mycobacterium tuberculosis : scope in diagnosis, vaccine design and therapy. Crit Rev Microbiol 37: 349-357.